Skip to main content
EMR
NYSE Manufacturing

Emerson 10-K: FY26 Sales $19.0B, Adjusted EPS $6.59; FY27 Guidance ~$7.25

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Industrial Machinery Stocks · Industrial
Sentiment info
Positive
Importance info
7
Price
$169.52
Mkt Cap
$94.558B
52W Low
$122.635
52W High
$172
52W Position info
38% above low
Off High info
1.4% below high
Rel. Volume info
1.0× avg
Market data snapshot near publication time

EMR sits 38% above its 52-week low of $122.635.

Summary

Emerson's FY2026 10-K confirms $19.0B of sales (+5%) and $6.59 adjusted EPS (+10%), and sets FY2027 guidance at ~$7.25 adjusted EPS with $3.8-3.9B of free cash flow.


Key Events · Earnings and Guidance · EMR

  • FY26 Sales $19.0B, Adjusted EPS $6.59

    Net sales rose 5% to $18,982M from $18,016M; adjusted diluted EPS from continuing operations rose 10% to $6.59 from $6.01, and GAAP diluted EPS was $4.79.

  • FY27 Guidance: ~$7.25 Adjusted EPS

    Management guides fiscal 2027 sales up approximately 5%, diluted EPS of approximately $5.70 and adjusted EPS of approximately $7.25, with operating cash flow of $4.3-4.4B and free cash flow of $3.8-3.9B.

  • Backlog Climbs to $9.6B

    Consolidated backlog was $9,593M at September 30, 2026 versus $8,629M a year earlier, with about 70% expected to convert to revenue within 12 months.

  • Debt Cut, Coverage at 9.0x

    Total debt fell to $12,175M from $13,116M, taking the debt-to-total-capital ratio to 37.0% from 39.3%; the interest coverage ratio improved to 9.0x from 8.5x.


Analysis · EMR · Manufacturing

The annual report locks in the numbers the market already saw in the November 4 pre-announcement, but it is the first audited, full-year document and the first place the complete FY2027 outlook appears in filing form: sales up ~5%, adjusted EPS ~$7.25, and $3.8-3.9B of free cash flow. A clean audit is confirmed as well (KPMG unqualified, no material weakness, no going-concern language), alongside a stronger balance sheet, with total debt down to $12.2B from $13.1B and interest coverage at 9.0x. Note that the pension mark-to-market accounting change adopted this year is a presentation shift, not a cash event. For holders, the takeaway is that the transformation story — software-heavy mix, $9.6B backlog, 53.4% gross margin — is now the audited baseline against which FY2027 will be measured.

How filings like this one have moved

In the 30 days to Nov 9, 2026, 36.6% of the 2965 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, EMR was trading at $169.52 on NYSE in the Manufacturing sector, with a market capitalization of approximately $94.6B. The 52-week trading range was $122.64 to $172.00. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

EMR - Latest Insights

EMR
Nov 04, 2026, 6:53 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $166.40
Real-time Price: $169.52 info
Change: +$3.12 (+2%) info
Market Cap: $94.558B info
EMR
Sep 15, 2026, 10:36 AM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $146.88
Real-time Price: $169.52 info
Change: +$22.64 (+15%) info
Market Cap: $94.558B info
EMR
Aug 06, 2026, 9:00 AM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $156.50
Real-time Price: $169.52 info
Change: +$13.02 (+8%) info
Market Cap: $94.558B info
EMR
Aug 04, 2026, 5:47 PM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $153.00
Real-time Price: $169.52 info
Change: +$16.52 (+11%) info
Market Cap: $94.558B info
EMR
Aug 04, 2026, 4:07 PM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $155.00
Real-time Price: $169.52 info
Change: +$14.52 (+9%) info
Market Cap: $94.558B info